ASTM has been volatile based on the recent market depreciation and is held at an extremely low stock price in relation to the market comps and 3 late stage clinical trials targeting niche cardiovascular indications. I updated the model post the last few weeks of downward pricing implying a valuation of $3.56 given the fully diluted shares outstanding with a Sum of the Parts estimation of $5.71 (discounted 20%) which is significantly above the current price of $1.42 and market cap of $40.12 M. Read more…
A team of scientists at the J. Craig Venter Institute announced that they have successfully created a living organism with a completely synthetic genome. Read more…
This prospectus relates to the public offering of up to 89.9 M shares of common stock, par value $.001 per share of Advanced Cell Technology (ACT or ACTC.OB). ACT entered into multiple convertible promissory notes and 3 unsecured convertible notes to JMJ Financial; some with a “Make Whole Amount” to the balance of the applicable JMJ Notes. However, ACT will not receive any of the proceeds from the sale (basically registering the shares) but, will pay the expenses of registering these shares. Read more…
Cryo-Save announced the European introduction of Cryo-Lip, a new product that allows the collection, processing and storage of a rich mixture of adult stem cells from liposuction aspirate (fatty tissue that is normally discarded). Read more…
Small life-sciences companies in the US will get funds in the form of tax credits or as a grant covering 50% of project development costs (for 2009 and 2010) for companies with fewer than 250 workers. The plan, part of the US healthcare overhaul approved in March, is expected to be open to hundreds of biotech, medical device and diagnostic companies that are both public and privately held. Read more…
StemSave, Inc cites a new technique conducted in Columbia University Medical Center’s Tissue Engineering and Regenerative Medicine Laboratory published in the current issue of the Journal of Dental Research about the body’s own stem cells to regenerate teeth. Read more…
Powerful stem cells made by reprogramming adult tissue could reduce the need for animal testing of new drugs, according to Professor Jamie Thomson, of the University of Wisconsin (WARF and Cellular Dynamics) could refine pharmaceutical development so that fewer animal experiments would be required. Read more…
The Maryland Stem Cell Research Commission has completed its evaluation of the 141 applications in response to its 3 official Requests for Applications (RFAs) during the FY10 funding cycle. The board of directors of the Maryland Technology Development Corporation (TEDCO) reviewed the Commission’s recommendations and approved 42 projects totaling $11.7 M in funding Read more…
NBS announced (5/20/10) the conversion of Convertible Redeemable Series C Preferred Stock (Series C Preferred) by RimAsia Capital Partners, LP (“RimAsia”), a principal shareholder. With the conversion of the Series C Preferred, NBS will no longer be required to pay the annual dividend and expects to recognize cash savings of $409 K per year. Read more…
ASTM announced the appointments of Sharon Watling, Pharm.D, as VP, Clinical and Regulatory, and Ronnda L. Bartel, Ph.D, VP, Chief Scientific Officer (formerly VP Technical Operations). Read more…
